WBA:NGS-Walgreens Boots Alliance Inc. (USD)

EQUITY | Pharmaceutical Retailers | Nasdaq Global Select

Last Closing

USD 11.87

Change

0.00 (0.00)%

Market Cap

USD 90.91B

Volume

0.01B

Analyst Target

USD 42.72
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Walgreens Boots Alliance Inc operates drug-stores chain in the United States. It provides consumer goods and services, pharmacy, and health and wellness services through drug-stores, as well as mail, and by telephone and online.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-26 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap
HITI High Tide Inc

+0.10 (+3.55%)

USD 0.25B
PETS PetMed Express Inc

+0.05 (+1.07%)

USD 0.10B
CJJD China Jo-Jo Drugstores Inc

-0.04 (-2.37%)

USD 0.01B
SCNX Scienture Holdings, Inc.

-0.28 (-7.00%)

N/A
MDVLQ MedAvail Holdings Inc

N/A

N/A

ETFs Containing WBA

PEY Invesco High Yield Equity.. 5.93 % 0.53 %

-0.23 (-1.14%)

USD 1.22B
DOGG First Trust Exchange-Trad.. 4.29 % 0.00 %

-0.16 (-1.14%)

USD 0.03B
RSPS Invesco S&P 500 Equal Wei.. 3.34 % 0.00 %

-0.57 (-1.14%)

USD 0.26B
SHRT Tidal ETF Trust 1.56 % 0.00 %

-0.09 (-1.14%)

USD 0.01B
ISPE:LSE iShares S&P 500 Equal Wei.. 0.27 % 0.00 %

N/A

USD 0.74B
SPED:LSE Invesco S&P 500 Equal Wei.. 0.24 % 0.00 %

-0.06 (-1.14%)

USD 0.23B
SPEQ:LSE Invesco S&P 500 Equal Wei.. 0.24 % 0.00 %

-0.03 (-1.14%)

USD 0.66B
XEWG:LSE Xtrackers S&P 500 Equal W.. 0.24 % 0.00 %

N/A

USD 0.10B
FCY 0.00 % 0.84 %

N/A

N/A
FCY:CA 0.00 % 0.95 %

N/A

N/A
FMK 0.00 % 0.70 %

N/A

N/A
IBDK 0.00 % 0.10 %

N/A

N/A
IVFVC 0.00 % 0.00 %

N/A

N/A
DWSH AdvisorShares Dorsey Wrig.. 0.00 % 0.00 %

+0.12 (+-1.14%)

USD 0.01B
FCW:CA 0.00 % 0.90 %

N/A

N/A
ICAN 0.00 % 0.50 %

N/A

N/A
IUSF:LSE iShares IV Public Limited.. 0.00 % 0.00 %

+3.75 (+-1.14%)

USD 0.29B
IUSZ:LSE iShares Edge MSCI USA Siz.. 0.00 % 0.00 %

+0.01 (+-1.14%)

USD 0.29B
IWFS:LSE iShares MSCI World Size F.. 0.00 % 0.00 %

+13.00 (+-1.14%)

USD 0.28B
IWSZ:LSE iShares IV Public Limited.. 0.00 % 0.00 %

+0.03 (+-1.14%)

USD 0.28B
VVAL:LSE 0.00 % 0.00 %

N/A

N/A
GBDV 0.00 % 0.00 %

N/A

N/A
GBLO 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Pharmaceutical Retailers) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 27.22% 100% F 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.22% 100% F 93% A
Trailing 12 Months  
Capital Gain -48.05% 50% F 17% F
Dividend Return 4.38% 100% F 70% C-
Total Return -43.68% 50% F 18% F
Trailing 5 Years  
Capital Gain -77.51% 100% F 17% F
Dividend Return 16.26% 50% F 66% D+
Total Return -61.25% 100% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain -20.21% 50% F 12% F
Dividend Return -15.92% 50% F 15% F
Total Return 4.29% 100% F 82% B
Risk Return Profile  
Volatility (Standard Deviation) 28.39% 75% C 65% D
Risk Adjusted Return -56.07% 50% F 12% F
Market Capitalization 90.91B 100% F 91% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Pharmaceutical Retailers) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 31.23 67% 31%
Price/Book Ratio 0.79 75% 82%
Price / Cash Flow Ratio 8.06 75% 34%
Price/Free Cash Flow Ratio -22.57 100% 94%
Management Effectiveness  
Return on Equity -75.97% 25% 24%
Return on Invested Capital -62.44% 40% 19%
Return on Assets 0.59% 75% 61%
Debt to Equity Ratio 77.01% 33% 31%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.